Takeda Pharmaceutical Company Limited share price today

Takeda Pharmaceutical Company Limited's share price was $21.07 at the close on 4 November 2026. It has been rising for 19 weeks. That is 19.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between $14 and $21, and at that close it was at the high of that range.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Takeda Pharmaceutical Company Limited is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 14 weeks in a row.

Over the last 10 years the share price moved −2% while the S&P 500 moved +261%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Takeda Pharmaceutical Company Limited declared JPY 100.00 per local share for Mar 2026, and JPY 396.00 over the last four reported quarters. It reports in Japanese yen, and one US-listed share can stand for several local shares, so we do not set this against the dollar price or show a yield.

Takeda Pharmaceutical Company Limited is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Takeda Pharmaceutical Company Limited earned JPY 113 B of net profit in the Jun 2026 quarter, −8.9% on the same quarter a year earlier. The full FY26 year was a loss of JPY 152 B. That is 9.3% of the quarter's revenue. The same quarter a year earlier earned JPY 124 B.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

5 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was −JPY 152 B (−241.2% on the year before).

Why profit moved: revenue changed +10.2% on a year earlier and the margin moved +1.1 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +71.3% and revenue +3.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit.

This company reports in Japanese yen, not US dollars, so the money charts are left out here. The figures in the text are in that currency (JPY); nothing is converted.

Takeda Pharmaceutical Company Limited reported JPY 1,220 B of revenue in the Jun 2026 quarter, +10.2% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 4 years it has grown 6.0% a year on average. The last full year, FY26, came in at JPY 4,506 B.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to JPY 4,619 B.

FY26 revenue was JPY 4,506 B, −1.7% on the year before.

Recent pace: the last four quarters grew +3.2% on average, against 6.0% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +3.1%, against +2.3% a year over the last 8 quarters (stabilising).

This company reports in Japanese yen, not US dollars, so the money charts are left out here. The figures in the text are in that currency (JPY); nothing is converted.

Takeda Pharmaceutical Company Limited's operating margin was 16.4% in the Jun 2026 quarter, 1.1 percentage points higher than the same quarter a year ago. Across 5 years it has been between 11.8% and 16.8%. The latest quarter is within that range.

Operating margin is what is left from every JPY 100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +1.1 percentage points on the year while gross margin changed +1.5 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 483% of Takeda Pharmaceutical Company Limited's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in JPY 1,041 B of operating cash against −JPY 152 B of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After JPY 176 B of spending on assets, JPY 865 B was left over as free cash.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

This company reports in Japanese yen, not US dollars, so the money charts are left out here. The figures in the text are in that currency (JPY); nothing is converted.

Takeda Pharmaceutical Company Limited does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent JPY 552 B on assets over the last 3 years. Averaged over those years that is 4.1% of FY26 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: JPY 552 B over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

This company reports in Japanese yen, not US dollars, so the money charts are left out here. The figures in the text are in that currency (JPY); nothing is converted.

Takeda Pharmaceutical Company Limited's P/E is 259.0×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple.

Takeda Pharmaceutical Company Limited's business is giving mixed signals. Revenue growth is rising from its low at +3.1% while profit growth is falling at −219.4%, so the lines disagree and each one tells part of the story. This is based on 12 quarters of 3 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: when the lines disagree, each line above matters more than any single label.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Takeda Pharmaceutical Company Limited earned a ROE of −2% in FY26. Its return on capital used (ROIC) is 1.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a −3.4% net margin and 0.29× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY26): a −3.4% net margin × 0.29× asset turnover × 2.09× leverage (assets divided by equity) ≈ −2.1% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 6.2% − 4.3% = +1.9 percentage points. The 4.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error.

The 6.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 5.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Takeda Pharmaceutical Company Limited has total debt of JPY 5,536 B against shareholder equity of JPY 7,559 B as of Jun 2026, so its debt is 0.73× its equity. Year by year, that ratio went from 0.85 in FY22 to 0.74 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

This company reports in Japanese yen, not US dollars, so the money charts are left out here. The figures in the text are in that currency (JPY); nothing is converted.

0.2% of Takeda Pharmaceutical Company Limited's tradable shares are in short positions, which are bets that the price will fall, so very few traders are betting against this stock. At normal trading volumes, closing those positions would take about 1.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Takeda Pharmaceutical Company Limited, the Z-score is 1.21. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 1.21 is inside the danger zone, so the balance sheet is a real risk.

There is no score against its industry: Takeda Pharmaceutical Company Limited is not among the largest members shown in this industry comparison for Drug Manufacturers - Specialty & Generic.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Takeda Pharmaceutical Company Limited is the largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 4 November 2026). It is the largest. Just below it: Teva Pharmaceutical Industries, Haleon plc, Zoetis Inc., United Therapeutics Corporation, Viatris Inc. and Neurocrine Biosciences, Inc.

Drug Manufacturers - Specialty & Generic companies close in size

1. Takeda Pharmaceutical Company Limited $66.4 billion
2. Teva Pharmaceutical Industries Limited $48.7 billion
3. Haleon plc $41.9 billion
4. Zoetis Inc. $36.8 billion
5. United Therapeutics Corporation $26.1 billion
6. Viatris Inc. $22.1 billion
7. Neurocrine Biosciences, Inc. $16.8 billion

All 51 Drug Manufacturers - Specialty & Generic companies, largest first

Companies close in size in other industries

259. Public Storage $66.6 billion · REIT - Industrial
260. Hewlett Packard Enterprise Company $66.5 billion · Communication Equipment
261. Takeda Pharmaceutical Company Limited $66.4 billion
262. Boston Scientific Corporation $66.4 billion · Medical Devices
263. Barrick Mining Corporation $66.2 billion · Gold

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.